Literature DB >> 16338425

Toxin conjugate therapy of cancer.

Lucas Wong1, Dick Y Suh, Arthur E Frankel.   

Abstract

Standard approaches to the treatment of malignancies include surgery, chemotherapy, and radiation. More recently, with understanding of these processes in molecular detail, biologics have become another important aspect of treatment. Conjugate toxins are biologics that combine a potent toxin with a peptide that will target cancer cells with minimal damage to normal tissues. This review will detail examples of these conjugate toxins and their targeted malignancies.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16338425     DOI： 10.1053/j.seminoncol.2005.08.002

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  6 in total

Review 1.  Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.

Authors:  Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

Review 2.  c-Met targeted therapy of cholangiocarcinoma.

Authors:  Matei-P Socoteanu; Frank Mott; Gianfranco Alpini; Arthur-E Frankel
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

3.  Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.

Authors:  Randall W Alfano; Stephen H Leppla; Shihui Liu; Thomas H Bugge; Meenhard Herlyn; Keiran S Smalley; Jennifer L Bromberg-White; Nicholas S Duesbery; Arthur E Frankel
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

4.  Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.

Authors:  Jeffrey M Schafer; Diane E Peters; Thomas Morley; Shihui Liu; Alfredo A Molinolo; Stephen H Leppla; Thomas H Bugge
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

Review 5.  Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy.

Authors:  José M Ferreras; Lucía Citores; Rosario Iglesias; Pilar Jiménez; Tomás Girbés
Journal:  Toxins (Basel)       Date:  2011-04-29       Impact factor: 4.546

Review 6.  Elderberries: a source of ribosome-inactivating proteins with lectin activity.

Authors:  Jesús Tejero; Pilar Jiménez; Emiliano J Quinto; Damián Cordoba-Diaz; Manuel Garrosa; Manuel Cordoba-Diaz; Manuel J Gayoso; Tomás Girbés
Journal:  Molecules       Date:  2015-01-30       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.